What is the recommended first-line treatment for tenosynovial giant cell tumor and the subsequent management options for unresectable or recurrent disease?

Tenosynovial Giant Cell Tumor: Treatment Recommendations

Surgery is the first-line treatment for localized TGCT and is frequently curative, while diffuse-type TGCT requires a more nuanced approach given high recurrence rates (40-60%) and functional loss after surgery—in these cases, CSF1R-targeted systemic therapies should be strongly considered as primary treatment or for unresectable/recurrent disease. 1

Treatment Algorithm by Disease Type

Localized TGCT (L-TGCT)

• Primary treatment: Complete surgical excision 1, 2
• This approach is frequently curative with low recurrence rates
• Surgery alone is sufficient for most localized disease

Diffuse-Type TGCT (D-TGCT)

Initial Management Decision Tree:

1. Asymptomatic or minimally symptomatic disease:

   • Consider active surveillance with regular MRI and clinical review 1
   • Surgery is increasingly recognized as NOT optimal for diffuse disease due to 40-60% recurrence rates and significant functional loss 1

2. Symptomatic diffuse disease requiring intervention:

   First consideration - Is complete resection feasible without major morbidity?

   • If YES: Surgical resection (open synovectomy preferred over arthroscopy for knee TGCT to reduce recurrence) 2
   • If NO or high surgical morbidity expected: Proceed directly to systemic therapy 1

Systemic Therapy for Unresectable or Recurrent Disease

The 2025 UK guidelines provide the most current evidence-based approach 1:

First-Line Systemic Options (CSF1R Inhibitors):

Preferred agents targeting the CSF1/CSF1R axis:

1. Pexidartinib - Only FDA-approved agent (USA only) 1

   • Objective response rate: 39% at week 25 3
   • Critical caveat: Hepatotoxicity risk requires careful monitoring

2. Vimseltinib (DCC-3014) - Emerging preferred option 1, 3

   • Objective response rate: 40% at week 25 3
   • Superior hepatic safety profile compared to pexidartinib 3
   • Should be considered preferred first-line systemic therapy when available

3. Imatinib 4, 2, 4

   • Can induce tumor stabilization or shrinkage 4
   • Evidence level: IV, C 4

4. Nilotinib 4, 1, 2

   • Alternative tyrosine kinase inhibitor option

5. Emactuzumab (RG7155) - Monoclonal antibody 1

Key principle: These therapies improve symptoms and function in symptomatic diffuse disease, though optimal treatment duration remains unclear 1

Radiotherapy Considerations

Radiotherapy is NOT a standard treatment for TGCT 1, despite demonstrating high local control rates 1, 5.

Rationale for limited use:

• TGCT affects young adults with benign disease
• Concerns about late radiation toxicity
• Risk of radiation-induced malignancy in young population 1

Exceptional circumstances where RT may be considered:

• Very selected patients with symptomatic residual or recurrent disease
• When systemic therapy is not an option 1
• After maximal cytoreductive resection to prevent progression 5
• Unresectable tumors at critical anatomic sites 1

When used: Typical dose is 36 Gy in 1.8-2.5 Gy fractions, achieving 100% local control with salvage therapy 5

Management of Recurrent Disease

For recurrent TGCT after surgery:

1. Assess resectability and prior treatment history
2. If multiple recurrences or unresectable: Systemic CSF1R inhibitor therapy is recommended 1, 2
3. Avoid repeated surgeries that lead to progressive joint dysfunction and potential need for joint replacement or amputation 6

Critical Practice Points

Multidisciplinary team review is essential for:

• Diffuse TGCT
• Recurrent disease
• Cases requiring complex procedures
• Unresectable disease 1, 7

Definition of unresectable TGCT:

• Disease involving vital structures where removal would cause unacceptable morbidity
• High risk of significant functional loss with surgery
• Multiple prior recurrences with progressive joint destruction

Common pitfall to avoid: Do not perform multiple surgical debulking procedures for diffuse TGCT, as this leads to cumulative joint damage, functional loss, and ultimately worse outcomes than primary systemic therapy 1

Evidence Strength Summary

The most recent and highest-quality evidence comes from the 2025 UK guidelines 1, which represent Level I, B evidence for systemic therapies in diffuse symptomatic TGCT. These supersede the 2018 ESMO guidelines 4 that rated imatinib/nilotinib as Level IV, C evidence, reflecting the significant evolution in TGCT management with newer CSF1R-targeted agents demonstrating superior efficacy and safety profiles.